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Abstract 
Fifteen million babies are born preterm every year and a significant number suffer from 
permanent neurological injuries linked to white matter injury (WMI). A chief cause of 
preterm birth itself and predictor of the severity of WMI is exposure to maternal-fetal 
infection-inflammation such as chorioamnionitis. There are no neurotherapeutics for this 
WMI. To affect this healthcare need, the repurposing of drugs with efficacy in other white 
matter injury models is an attractive strategy. As such, we tested the efficacy of 
GSK247246, an H3R antagonist/inverse agonist, in a model of inflammation-mediated 
WMI of the preterm born infant recapitulating the main clinical hallmarks of human brain 
injury, which are oligodendrocyte maturation arrest, microglial reactivity, and 
hypomyelination. WMI is induced by mimicking the effects of maternal-fetal infection-
inflammation and setting up neuroinflammation. We induce this process at the time in the 
mouse when brain development is equivalent to the human third trimester; postnatal day 
(P)1 through to P5 with i.p. interleukin-1β (IL-1β) injections. We initiated GSK247246 
treatment (i.p at 7mg/kg or 20mg/kg) after neuroinflammation was well established (on 
P6) and it was administered twice daily through to P10. Outcomes were assessed at P10 
and P30 with gene and protein analysis. A low dose of GSK247246 (7 mg/kg) lead to a 
recovery in protein expression of markers of myelin (density of Myelin Basic Protein, MBP 
& Proteolipid Proteins, PLP) and a reduction in macro- and microgliosis (density of 
ionising adaptor protein, IBA1 & glial fibrillary acid protein, GFAP). Our results confirm the 
neurotherapeutic efficacy of targeting the H3R for WMI seen in a cuprizone model of 
multiple sclerosis and a recently reported clinical trial in relapsing-remitting multiple 
sclerosis patients. Further work is needed to develop a slow release strategy for this agent 
and test its efficacy in large animal models of preterm infant WMI. 
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1. Introduction 
The central and peripheral immune systems directly influence the cellular and hence 
functional integrity of the brain. The immune factors involved in an inflammatory response 
can provoke beneficial as well as deleterious effects, and their imbalance contributes to 
the aetiology of many neurodegenerative diseases (Hagberg et al., 2015; Yang et al., 
2002). One such condition is brain damage in prematurely born infants, a condition of 
societal concern due to its continuing increase in incidence without available treatments 
(Lim et al., 2012; Mento and Nosarti, 2015). Every year 15 million babies are born before 
37 weeks of gestation, accounting for approximately 11% of all live births globally(WHO, 
2012; Blencowe et al., 2012). The frequency and severity of adverse outcomes rise with 
decreasing gestational age and poorer quality of care, with almost 10% of the infants born 
before 33 weeks developing cerebral palsy, and approximately 33% developing chronic 
cognitive and neuropsychiatric disorders (Arnaud et al., 2007; Delobel-Ayoub et al., 
2009). However, even when infants are born close to term, they are still at significantly 
higher risk of lifelong cognitive and psychiatric problems (Heinonen et al., 2015; Mento 
and Nosarti, 2015). 
 
A significant neuroanatomical feature of the brain damage observed in preterm born 
infants is a chronic failure in myelination, referred to as preterm white matter injury (PWMI) 
(Back et al., 2007; Salmaso et al., 2014; Van Steenwinckel et al., 2014; Verney et al., 
2012). Myelin is formed by the extensive cellular processes of mature oligodendrocytes, 
which mature stepwise from oligodendrocyte progenitor cells through the sequential 
stages of pre-oligodendrocytes and premature oligodendrocytes (for review see, Mitew 
et al., 2013). Neuropathological analysis of human post-mortem tissues and animal 
models reveal that the mechanistic substrate of PWMI is multi-fold, including damage due 
to inflammatory cytokines and oxidative stress (for discourse see, Paneth, 2018). 
Exposure of the pre-term born infant to inflammation occurs due to maternal-fetal 
infection-inflammation which is both a cause of pre-term birth(Goldenberg et al., 2008; 
Malaeb and Dammann, 2009) and a chief predictor of brain injury. Maternal-fetal 
infection-inflammatory insults in preterm born infants come from sources including 
ascending infections leading to chorioamnionitis that are often sub-clinical (Wu et al., 
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2009) and postnatal sepsis (O'Shea et al., 2013). The link to brain injury from these pre-
natal and post-natal inflammatory exposures is that systemic inflammation propagates 
into the brain via endothelial cytokine receptors leading to neuroinflammation(Serrats et 
al., 2010). The mechanistic substrate by which neuroinflammation damages brain 
development includes as mentioned above excess cytokine and reactive oxygen species 
production, but also the disruption of the numerous developmental functions of microglia, 
reviewed in (Tay et al., 2017). A failure to mature or delayed maturation of OPCs is linked 
to damage to the processes of developmental myelinogenesis (Billiards et al., 2008; 
Buser et al., 2012; Verney et al., 2010) and reviewed recently in (van Tilborg et al., 2016). 
Fortuitously, oligodendrocyte progenitor cells remain in the brain in the same numbers 
even due to toxic insults associated with PWMI providing a therapeutic opportunity 
through the induction of these oligodendrocyte progenitor cells to differentiate and mature 
into myelin-forming oligodendrocytes. Such a therapeutic approach is being developed 
for multiple sclerosis to induce the remyelination of sclerotic plaques with demyelinated 
neuronal processes (Fancy et al., 2011; Franklin and Ffrench-Constant, 2008; Franklin et 
al., 2012). Clinical trials include anti-Lingo antibodies (Tran et al., 2014) and a positive 
outcome from a trial of the histamine receptor 3 (H3R) antagonist GSK239512 
(Schwartzbach et al., 2017). It is conceivable that the same therapeutic approach could 
also benefit PWMI. However, significant differences exist between PWMI and multiple 
sclerosis in their disease aetiology, the oligodendrocyte progenitor cells in infants and 
adults may have different properties, and the drug target mechanism in PWMI is to induce 
myelinogenesis for the first time, whereas remyelination is the target mechanism in 
multiple sclerosis. Therefore, proof of principle studies with drugs hypothesized to induce 
oligodendrocyte progenitor cell maturation are needed in relevant preclinical PWMI 
models to justify PWMI clinical trials. 
High-value targets in the hunt for therapies for multiple sclerosis in the past decade have 
been the histamine receptors (HR), (see reviews, Panula and Nuutinen, 2013; Saligrama 
et al., 2012), and the H3R, in particular. As such, the potential neuroprotective role of 
H3R seems worthy of investigating in perinatal brain injury given the common role of 
oligodendrocytes mentioned above. Despite sharing a high affinity for histamine, the four 
HRs have low sequence homology (e.g. H4R shares approximately 37% identity with the 
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H3R, but less than 20% with the H2R and H1R). HRs are G-protein–coupled receptors 
(GPCRs), and although there is some reported cell specificity that remains incompletely 
understood H3R, and H4R share downstream signalling via the Gαi subunit, acting via 
protein kinase A (PKA) (Hu and Chen, 2017; Panula and Nuutinen, 2013) Furthermore, 
additional signalling cascades also activated by H3R, include the mitogen-activated 
protein kinase, phospholipase A2 and phosphoinositide 3-kinase (PI3K) pathways. H3R 
acts as an autoreceptor in histaminergic neurons and as a heteroreceptor in non-
histaminergic neurons and regulate the release of various other neurotransmitters, 
including GABA, glutamate, acetylcholine and noradrenaline. An H3R-penetrant 
antagonist / inverse agonist, named GSK247246 was initially identified in an in vitro assay 
for its ability to induce the differentiation of OPCs into oligodendrocytes. Furthermore, 
GSK247246 has recently been described to enhance remyelination in vivo following 
demyelination induced by cuprizone (Chen et al., 2017). 
 
In the present study, we tested the myelin-inducing ability of GSK247246 in a mouse 
model of PWMI induced by neuroinflammation driven by systemic inflammation (Favrais 
et al., 2011; Krishnan et al., 2017; Shiow et al., 2017). This paradigm mimics the clinical 
events of clinically silent perinatal infection/inflammation that are common in preterm born 
infants with WMI (Wu et al., 2009). GSK247246 was administered after the establishment 
of the injurious inflammatory stimuli to directly assess its restorative abilities in a clinically 
relevant treatment paradigm. We observed that GSK247246 was able to reverse the 
blockade of developmental myelination induced by the neuroinflammatory insult in 
several brain regions, and also appeared to possess anti- neuroinflammatory activity. Our 
study is the first demonstration of a systemically administered compound capable of 
reversing the blockade of myelination in a preclinical model of PWMI.  
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2. Material and Methods 
2.1. Animals and induction of neuroinflammatory driven WMI via IL-1β administration 
Experimental protocols were approved by the institutional guidelines of the Institut 
National de la Santé et de la Recherche Scientifique (Inserm) France and met the 
guidelines for the United States Public Health Service's Policy on Humane Care and Use 
of Laboratory Animals (NIH, Bethesda, Maryland, USA). The protocol was approved by 
the Bichat-Robert Debre ethical committee under the reference 2011-14/676-0053. OF1 
strain mice purchased from Charles River (L’Arbresle, France) and born in our animal 
facility were used in all experiments. Animals were housed under a 12 h light-dark cycle, 
had access to food and water ad libitum and were weaned into same-sex groups at P21. 
On P1 pups were sexed and where necessary litters were culled to 9-11 pups. 
Assessments of injury and outcomes were made only in male animals as females do not 
display PWMI in response to this paradigm. IL-1β exposure to set up a systemic and then 
complex central neuroinflammatory response was carried out as previously described 
(Favrais et al., 2011). Briefly, mice received twice a day (bid) from P1 to P4, and once on 
P5, a 5 µl intra-peritoneal (i.p.) injection of 10µg/kg/injection recombinant mouse IL-1β in 
phosphate buffered saline (PBS; R&D Systems, Minneapolis, MN) or PBS alone (Figure 
1). For immunohistochemical analysis at P10, animals came from at least five litters per 
group, and at P30 the animals came from at least ten litters per group. For analysis via 
qRT-PCR, animals came from at least five litters per group. 
 
2.2. Pharmacokinetic and pharmacodynamic studies of GSK247246 
GSK247246 (N-aryl-1,3,4-oxadiazole-2-amine) has a MW of 341.4, it crosses the blood 
brain barrier, its solubility is 1.47 mg/ml (HCl salt form) at pH7.4, its hydrophilicity is 
 cLogP=3.4 and its Pharmaceutical Formulation Intermediates score is 4.1. We dissolved 
GSK247246 in 50 mM of sodium citrate buffer (pH5) at the concentration of 10 mg/ml. A 
pilot pharmacokinetic study was conducted to enable dose selection for pharmacology 
study. Male naïve OF1 mice at P10 received an i.p. injection of GSK247246 at the dose 
of 20 mg/kg. We collected blood and brain samples at 6-time points from 0.5 to 24 hours 
post dosing, and the samples were analysed using a method based upon protein 
precipitation with acetonitrile followed by LC/MS/MS analysis (with the precursor-to-
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product ion transition: m/z 342.2 -> m/z 135.8). The derived pharmacokinetic parameters 
of blood and brain, the unbound compound concentrations in brain (determined with 
unbound fraction in brain tissue, data not shown here), in vitro potency in oligodendrocyte 
progenitor cell differentiation assay and in vivo pharmacokinetics data of GSK247246 in 
adult mice cuprizone demyelination model (unpublished data) were used to predict the 
efficacious dose and dosing regimen in neonatal mice via compartmental 
pharmacokinetic modelling and simulation with Phoenix software [WinNonlinTM (WNL), 
Version 6.3 (Pharsight Corp.)], targeting same or longer coverage above in vitro EC90 in 
the pharmacodynamic study.  
 
For the GSK247246 pharmacodynamic study, neonatal mice received bid from P6 to P10 
an 8 µl i.p. injection of a low or high dose of GSK247246 (7 mg/kg and 20 mg/kg, 
respectively) as determined by pharmacokinetics dose prediction stated above, or 50 mM 
sodium citrate buffer (pH5) alone (vehicle). At 2 hours post the last injection on P10, blood 
and brain samples (one hemisphere of the brain) were collected from each mouse to 
determine drug concentration in blood and brain samples with the same method 
described above. 
 
2.3. Immunohistochemistry 
At P10, we collected brains for preparation of frozen sections following intracardial 
perfusion with 4% paraformaldehyde-phosphate buffer solution under isofluorane 
anaesthesia. Brains were post-fixed for 4 h at room temperature and then following at 
least three days in 30% sucrose in PBS the brains were embedded in 15% sucrose-7.5% 
gelatine solution and frozen at -80°C before sectioning at 16 µm. At P30 brains were 
processed to paraffin sections by immediate immersion for 6-7 days in 4% formaldehyde 
at room temperature before dehydration, embedding in paraffin and sectioning at 12 µm.  
 
Primary antibodies used were anti-cleaved caspase-3 (1:500, Cell Signaling, Beverly, 
MA, USA), anti-Ki67 (1:1000, BD Biosciences, San Jose, CA, USA), anti-Glial Fibrillary 
Acidic Protein (GFAP, 1/500, Glostrup, Denmark), anti-IBA1 (1:2000, Wako Pure 
Chemical Industries, Osaka, Japan), anti-NG2 (1:200, Chemicon, Temecula, CA, USA), 
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anti-Adenomatosis Polyposis Coli (APC, 1:2000, Calbiochem, CA, USA), anti-Myelin 
Basic Protein (MBP, 1:500, Chemicon), anti-proteolipid protein 1 (PLP, 1/400, Abcam, 
Cambridge, UK), anti-myelin-associated glycoprotein (MAG, 1/100, Santa Cruz 
Biotechnology, Santa Cruz, CA, USA), and anti-NEUN (1:500, Chemicon). 
Immunohistochemistry staining was performed as previously described (Favrais et al., 
2011; Schang et al., 2014). Nuclei were counterstained with DAPI (Sigma, St-Quentin 
Fallavier, France). A blinded experimenter performed all analyses. The intensity of MBP, 
PLP and MAG immunostaining was assessed via densitometric analysis as previously 
described using the ImageJ software package (http:// rsbweb.nih.gov/ij/) (Favrais et al., 
2011). Cell counts for cleaved caspase-3, Ki67, GFAP, IBA1, NG2, NEUN and APC were 
performed in four sections per animal for each defined brain structure and are expressed 
as positive cells per square micrometre. In addition, to validate the expression of the 
target H3 receptor, anti-H3R primary antibodies (1:500, Sigma) were tested on sections 
from control P5 brains processed as described for P10 brains.  
 
2.4. Neural tissue dissociation and magnetic-activated cell sorting 
At P5 and P10, we collected brains for cell dissociation and O4-positive and CD11b-
positive cell enrichment using a magnetic coupled antibody extraction technique (MACS), 
as previously described (Krishnan et al., 2017; Schang et al., 2014) and according to the 
manufacturer’s protocol (Miltenyi Biotec, Bergisch Gladbach, Germany). Pre-
oligodendrocytes express the O4 antigen on their cell surface (Back et al., 2001). In brief, 
we pooled brains (n=3 at P5 and n=2 at P10) and after removing the cerebellum and 
olfactory bulbs they were dissociated using the Neural Tissue Dissociation Kit containing 
papain. From the resulting brain homogenate cells were enriched by MACS, using the 
anti-O4 or anti-CD11b MicroBeads and after elution, we centrifuged the isolated cells for 
5 minutes at 600 g and then conserved them at -80oC. The purity of the eluted fraction 
was verified using qRT-PCR for GFAP, NEUN, OLIG2 and IBA1 as previously described 
(Krishnan et al., 2017; Schang et al., 2014) and revealed gene expression levels 95% 
lower than found in the respective primary cultures of astrocytes, neurons or microglia. 
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2.5. Microarray analysis and quantitative reverse-transcriptase polymerase-chain 
reaction 
Miltenyi Biotec performed microarrays on a total of 24 MACS extracted O4 and CD11b 
enriched cell samples from P5 or P10 mice exposed to IL-1β or PBS (Krishnan et al., 
2017). Also, we collected frontal lobes from P10 mice exposed to IL-1β or PBS for mRNA 
extraction and subsequent qRT-PCR for genes involved in oligodendrocyte maturation 
and myelination. Preparation of samples for array analysis and qRT-PCR, primer design, 
and PCR protocol were similar to that previously described (Chhor et al., 2013; Husson 
et al., 2005; Krishnan et al., 2017). We have supplied primer sequences in Supplementary 
Table 1. Gapdh (glyceraldehyde-3-phosphate dehydrogenase gene) was chosen to 
standardise the quantitative experiments based on reference gene suitability testing. We 
expressed the relative quantities of mRNA as the specific ratio between the gene of 
interest and Gapdh.  
 
2.6. Statistical and microarray analysis 
For the analysis of Statistical analysis of all data was performed using GraphPad Prism 
version 7.0 (GraphPad Software, San Diego, CA). For all results, we verified that data 
was normally distributed with the D’Agostino and Pearson omnibus normality test. We 
used a one-way ANOVA followed by a Newman-Keuls post hoc test for Gaussian 
distributions, and a Kruskal-Wallis test followed by a Dunn's post hoc test for non-
Gaussian distributed data. The Agilent feature extraction software was used to process 
microarray image files. We only included signal intensities above background. Signal 
intensity values were background subtracted and uploaded following instructions by 
Miltenyi Biotec GmbH (Stefan Tomiuk) and Perkin Elmer (Matt Hudson) into GeneSifter 
Analysis Edition v4.0 (http://login.genesifter.net/) for further analysis as previously 
described (Gustavsson et al., 2007). The pre-processed signal intensity values were 
median normalised, and the gene expression in neuroinflammatory and PBS controls 
were compared at P5 and P10 using t-test (p<0.05) with Benjamini-Hochberg multiple 
testing correction.  
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3. Results 
3.1. Pharmacokinetic study 
3.1.1. Pilot pharmacokinetics and dose selection 
Fast distribution to blood and brain equilibrium of GSK247246 (within 30 minutes), a half-
life of 3.7 hours in blood and 4.1 hours in the brain, were observed in naïve neonatal mice 
post single i.p. dose at 20 mg/kg. The average brain-to-blood ratio ranged 6-8 at various 
time points (Figure 2A). We obtained compartmental pharmacokinetics parameters 
including volume, absorption and elimination rate constants through a compartmental 
modelling approach. Specifically, we simulated the different doses based on the pilot 
pharmacokinetics data at 20 mg/kg. Assuming a direct pharmacokinetics-
pharmacodynamic relationship and the same efficacious exposure as cuprizone model, 
20 mg/kg bid and 7 mg/kg bid was predicted to introduce free brain concentration higher 
than in vitro EC90 for 22 hours and 16 hours on each day of treatment in mice 
(pharmacokinetics modelling and simulation results not shown here). We selected two 
doses in order to demonstrate dose-response in the pharmacodynamic study. 
 
3.1.2. End-phase pharmacokinetics in the pharmacodynamic study 
GSK247246 concentrations in blood and brain at 2 hours post last dose were determined. 
We observed proportional compound concentrations in the blood and the brain in the two 
groups (Figure 2B), which indicated a linear pharmacokinetics at these two doses. The 
data at 20 mg/kg was comparable to the blood and brain data in the pilot study, suggesting 
a negligible accumulation after repeat dosing, which was aligned with relatively short half-
lives of GSK247246 in both blood and brain compartments. We observed a consistent 
brain-to-blood ratio in all animals with an average of 5.4 ± 1.0. 
 
3.2. H3R expression 
Immunohistochemistry performed on control P5 brains confirmed the expression of the 
H3R on both white matter and grey matter cells (Figure 3A-B-C). Microarray data 
confirmed the expression of the H3R mRNA in O4-positive cells and CD11B-positive cells 
at both at P5 (Supplementary Table 2), and P10 (not shown, see(Krishnan et al., 2017)) 
and that neuroinflammation did not affect this expression. 
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3.3. Oligodendrocytes and myelination  
We observed similar damage to oligodendrocytes and myelin proteins as we have 
previously reported in our model of PWMI associated with systemically driven 
neuroinflammation at P10 and P30 (Favrais et al., 2011; Schang et al., 2014). 
Specifically, at P10, when comparing PBS injected animals to PWMI animal there is a 
decreased density of APC-positive mature oligodendrocytes (Figure 4A) and an 
increased density of NG2-positive immature oligodendrocytes (Figure 4B) due to 
neuroinflammatory injury. Animals subjected to neuroinflammation and treated with a low 
dose of GSK247246 showed a significant reduction of the injury associated increase in 
the density of NG2-positive cells (Figure 4B). The high dose of GSK247246 had no 
significant effect on NG2 or APC cell numbers from neuroinflammatory injury only 
parameters (Figure 4). 
Specifically, at P30 when comparing PBS injected animals to PWMI animals in the 
sensorimotor cortical white matter and the basal ganglia the expression of MBP was 
significantly reduced (Figure 5); in the anterior commissure, cingulate white matter, 
corpus callosum and external capsule PLP expression was significantly reduced (Figure 
6); and in corpus callosum and cingulate white matter MAG expression was significantly 
reduced (Figure 7). The administration of 7 mg/kg/injection GSK247246 between P6 and 
P10 in our model of PWMI prevented the decrease of MBP expression in sensorimotor 
cortical white matter only (Figure 5A-B); of PLP in the anterior commissure, cingulate 
white matter and external capsule (Figure 4); and of MAG in the corpus callosum and 
cingulate white matter (Figure 5). Increasing the dosage of GSK247246 (20 
mg/kg/injection) resulted in less widespread neuroprotective effects on myelin markers 
(Figures 5-7). 
Gene expression analysis by qRT-PCR on P10 frontal lobes showed that PWMI group 
animals had a decreased expression of Mbp, Mag, Myelin oligodendrocyte glycoprotein 
(Mog), Gap junction gamma-2 (Gjc2 or connexin-46), Early growth response 1 (Egr1) and 
Fos mRNA when compared to controls (Figure 8). Low and high doses GSK247246 
further decreased the expression of Egr1 mRNA, GSK-7 (but not GSK-20) reduced 
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expression of Dusp, but no other significant effect on mRNAs were observed, when 
compared to the PWMI group (Figure 8).  
 
3.4. Proliferation, cell death, astrocytes, microglia, and neurons  
The induction of PWMI via systemically driven neuroinflammation or treatment with 
GSK247246 did not affect the density of Ki67-positive cells in the ventricular zone at P10 
(data not shown). Induction of PWMI caused at P10 an increased density of cleaved 
caspase-3-positive cells in corpus callosum but not in sensorimotor cortical white matter, 
cingulate white matter and external capsule (Figure 9). However, overall cell death in this 
model is very low (≤1 cell per 𝑢m2). The low dose of GSK247246 in our PWMI model had 
no significant effect on cleaved caspase-3-positive cell number when compared to injury 
only, but the high dose of GSK247246 significantly exacerbated cell death in three of the 
four studied regions (Figure 9). There was no significant effect on the density of GFAP-
positive cells in the four studied regions at P10 in respect to the effects of the 
neuroinflammatory challenge, or GSK247246 treatments (Figure 10). However, in the 
PWMI group at P30 there was a significant increase in the density of GFAP-positive cells 
in the cingulate white matter but not in the three other studied regions (Figure 9A-B). The 
low and the high dose of GSK247246 prevented this delayed and persisting astrogliosis 
induced by systemically driven neuroinflammatory injury (Figure 9A-B). In the PWMI 
group there was a significant increase in the density of IBA1-positive cells in the cingulate 
white matter at P10 (Figure 11A) and the sensorimotor cortical white matter at P30 (Figure 
11B) but not in the other studied regions. The low dose of GSK247246 prevented this 
microgliosis in the PWMI group (Figure 10B-C). Induction of PWMI had no effect on the 
number of NEUN-positive cells in the P30 sensorimotor cortex as previously reported for 
this model (Favrais et al., 2011) and this was also not altered by treatment with 
GSK247246 (data not shown).
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4. Discussion 
In our model of inflammation-associated white matter injury of the preterm born infant, 
treatment with a low dose of GSK247246 (7 mg/kg), an H3R antagonist/inverse agonist, 
lead to an improvement in protein expression of markers of myelin and a reduction in 
gliosis. Of note, we initiated treatment only after the animals had already experienced five 
full days of harmful neuroinflammation, known to cause maturation blockade of 
oligodendrocytes (Favrais et al., 2011; Schang et al., 2014). As prenatal exposure to 
inflammation (Baumbusch et al., 2016; Chafer-Pericas et al., 2015; Tronnes et al., 2014) 
and prenatal changes in the brain have been observed in infants who go on to be born 
preterm (Thomason et al., 2017) this efficacy with a delayed start provides significant 
clinical relevance to our study. Our results confirm the neurotherapeutic effects of 
targeting the H3R for white matter injury seen in a cuprizone model of multiple sclerosis 
(Wang et al., 2014) and a recently reported clinical trial in relapsing-remitting multiple 
sclerosis patients (Schwartzbach et al., 2017). Our animal model is specifically designed 
to model inflammation of the type found in many preterm born infants whose mothers had 
sub-clinical infections (McElrath et al., 2008; Palmsten et al., 2018; Wu et al., 2009), in 
contrast to severe events of sepsis or fulminant chorioamnionitis and funisitis. We wish 
to highlight that the predominate reason for this is that previous post-mortem data from 
our lab and from others of preterm born infant neuropathology shows that oligodendrocyte 
cell death is not a major contributor to injury, but that microgliosis and hypomyelination 
are observed (Billiards et al., 2008; Verney et al., 2010; Verney et al., 2012). Our animal 
model captures these clinical features, of very limited cell death, microgliosis and eventual 
hypomyelination (Favrais et al., 2011; Schang et al., 2014; Van Steenwinckel et al., 2018). 
Overall the data in this study on neuropathological findings and neuroinflammatory events 
associated with neuroinflammation alone was similar to what we have published 
previously (Favrais et al., 2011; Krishnan et al., 2017; Schang et al., 2014; Shiow et al., 
2017; Van Steenwinckel et al., 2018).  
Unfortunately, in our neuroinflammation-mediated WMI model, the dose of 20 mg/kg of 
GSK247246 increased cell death in regions of white matter (but not in the cortex) and 
failed to provide any therapeutic action; we ascribe this effect to pharmacokinetics 
overshoot. In this study, an oscillating pharmacokinetics was expected during repeat 
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dosing, with over 10-fold concentration drop from Cmax to Ctrough. This expectation was 
based on the pharmacokinetic profile and a relatively short half-life of GSK247246 
demonstrated in the single-dose pharmacokinetic analysis. However, in order to maintain 
enough free GSK247246 in the brain for the desired duration, overall GSK247246 
concentrations had to be boosted with higher doses, which may have led to unexpected 
toxicity associated with Cmax. Observations in this study of toxicity due to dose are in 
contrast to the aforementioned multiple sclerosis model (cuprizone), in which GSK247246 
demonstrated the efficacy of remyelination at 30 mg/kg, bid oral dosing in adult C57BL6/J 
mice, with no observable side effects (Wang et al., 2014). Additional formulation work to 
stabilise the release of the compound (slow release) or target the drug specifically to 
oligodendrocytes would allow us to lower the dose while maintaining therapeutic levels of 
the compound must be critical next steps in the translation of this drug for the perinatal 
population. In addition to effects of dosing, to understand the differences between toxicity 
data from the current neonatal model and the adult multiple sclerosis model we should 
look to differences in oligodendrocyte progenitor cell biology in the developing and adult 
central nervous system. These include, but are not limited to, differences in antigen 
markers, growth factor responsiveness, motility, cell cycle, and increased vulnerability to 
oxidative stress (Craig et al., 2003; Semple et al., 2013; van Tilborg et al., 2016). As such, 
we cannot rule out that oligodendrocyte progenitor cell sensitivity and tolerability to 
GSK247246 might differ during development (the process of myelinogenesis) and 
adulthood (remyelination following demyelination). The potential toxicity related to high 
dose in neonates might also indicate different tolerability and sensitivity of 
oligodendrocyte progenitor cells in different pathological conditions, i.e. a peripheral 
inflammation induced hypomyelination vs. centrally focussed toxin-induced 
demyelination.  
 
The neurotherapeutic effects of GSK247246 against PWMI are also supported by positive 
effects of another H3R antagonist/inverse agonist GSK239512 on lesion remyelination in 
a small cohort of human relapsing-remitting multiple sclerosis patients (Schwartzbach et 
al., 2017). Modulation of the neuroinflammatory responses are considered to be the chief 
therapeutic effects of H3R modulation either by direct effects on innate or adaptive 
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immune cells (Ferreira et al., 2012; Saligrama et al., 2013; Saligrama et al., 2012; 
Teuscher et al., 2007) discussed further below, or via effects on pathways innervating 
immune tissues (Krementsov et al., 2013). Nevertheless, direct effects on 
oligodendrocytes also cannot be excluded in this study. Specifically, in our animal model 
of white matter injury of the preterm born infant oligodendrocyte maturation arrest is 
induced via the neuroinflammatory actions of microglia (Krishnan et al., 2017); mimicking 
observations made by our group and others regarding injury seen in human preterm born 
infants (Billiards et al., 2008; Verney et al., 2012). As such, an obvious target to improve 
outcome in this model is a direct action on oligodendrocytes to stimulate maturation, and 
as such myelination. Oligodendrocytes express the H3R protein, and H3R mRNA 
constitutively with no effects of PWMI driven by systemic inflammation. This expression 
of H3R demonstrates that these cells are direct targets, even in the context of 
neuroinflammatory injury, an important observation as neuroinflammation itself has been 
shown to modulate cell pathway expression in oligodendrocytes (Gottle et al., 2010). A 
plausible mechanism for a direct positive effect of GSK247246 on oligodendrocyte 
maturation is the Ga1 mediated GPRC signalling via H3R. This GPRC signalling pathway 
is conversely responsible for negatively regulating oligodendrocyte maturation following 
GPR17 activation, via actions on cAMP-PKA (Fumagalli et al., 2011; Simon et al., 2016). 
 
Further data on oligodendrocytes was our observation of discrepancies between the 
expression of the myelin proteins (improved with GSK247246) and myelin genes (no 
change with GSK247246). Two hypothesis arise to explain this, (1) mechanisms of post-
translational mRNA modifications and mRNA stability are responsible for protein 
expression and (2) that the total cortical sampling for mRNA analysis hid the positive 
regional effects of the drug. Importantly, we are confident that our measures of improved 
myelin proteins reflect improvements in brain structure that are the aim of this study.  
 
This study expands our understanding of the model of neuroinflammation linked WMI, 
demonstrating for the first time that there is a delayed (P30 only) astrocytic gliosis, 
although this was observed only in the corpus callosum. Delayed (or Tertiary) phase 
changes in the brain effect long-term brain health (Fleiss and Gressens, 2012), and 
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GSK247246 prevented this delayed white matter astrogliosis. Astrocytes express 
histamine receptors, including H3R (Xu et al., 2018), to support that astrocytes may be a 
direct target of GSK247246 but alternatively, it is likely that this reduction in delayed 
gliosis is an indirect effect caused by improvements in microglia and oligodendrocytes at 
the earlier time point. As GFAP expression typically reduces with increasing age in the 
mouse (see review, Middeldorp and Hol, 2011), further work is needed to ascertain 
whether this change at P30 may represent an altered developmental profile.  
 
Microglial activation plays a role in the pathological processes of almost all injuries and 
disorders for the brain (Prinz et al., 2011; Siskova and Tremblay, 2013), including our 
WMI model (Krishnan et al., 2017), with limited exceptions (Chhor et al., 2017). Microglia 
express all four HR (Ferreira et al., 2012) including in the developing brain (Krishnan et 
al., 2017).  As part of in-house screening for pro-myelinogenic target molecules, via 
analysis of MBP expression by oligodendrocyte progenitor cells co-cultured with LPS-
activated BV2 microglia, this compound improved myelination by modulating microglial 
activity. That microglia could be a direct target of GSK247246 is further supported by our 
observations that microglial express mRNA for H3R and that GSK247246 reduced the 
increase in the density of IBA1-positive microglia in specific brain regions at different ages 
in our model of PWMI. 
 
We only began administering GSK247246 after animals had been exposed to 5 days of 
injurious inflammation and we provided twice daily injections of GSK247246 from P6 
through to and including P10; we wish to highlight two issues related to this paradigm. 
Firstly, this paradigm mimics a plausible clinical dosing regimen as pre-natal maternal-
fetal infection/inflammation is often clinically silent, and precipitates spontaneous pre-
term birth (Hillier et al., 1993; Wu et al., 2009). As such, infants are born following 
exposure to inflammatory injury, and changes to the brain have been observed prenatally 
in fetuses later delivered preterm (Thomason et al., 2017). Secondly, we observed while 
performing this study alongside other projects and compared to historical data that 
injecting the pups from P5-P10 with PBS in and of itself exacerbated the injury in the IL-
1β alone group, who had IL-1β from P1-P5 and then PBS from P6-P10. Experimental 
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design encompassing heightened / persisting stress is clinically relevant (Brummelte et 
al., 2012) and reinforces the utility of this drug as a neurotherapeutic with clinical potential. 
 
In summary, in a clinically relevant model of WMI of the preterm infant, low dose treatment 
with GSK247246 was able to recover injury to the white matter, and reduce micro- and 
astroglial reactivity. As this drug functions to recover WMI in the immature brain even with 
a delay to the administration further testing in large preclinical models of white matter 
injury are justified. 
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8. Figures 
 
 
Figure 1. Outline of the model of inflammation-associated white matter injury of the 
preterm infant. Use of P1-P5 mice to model the preterm infant brain is supported by 
comparative studies of brain growth and oligodendrocyte maturation (Back et al., 2001; 
Dean et al., 2011; Dobbing and Sands, 1979) and reviewed in (Semple et al., 2013). Full 
descriptions of the model including systemic and central inflammatory response and 
neuropathology are available within these references (Favrais et al., 2011; Krishnan et 
al., 2017; Schang et al., 2014; Shiow et al., 2017; Van Steenwinckel et al., 2018). 
Abbreviations: IL-1β, interleukin-1β; i.p., intraperitoneal injection; P, postnatal day of life 
with P0 as day of birth; bid, twice daily; ≅,	approximately equal to; OPC, oligodendrocyte 
progenitor cell.  
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Figure 2. Pharmacokinetic data for GSK247246. A. GSK247246 concentrations in blood 
(indicated in black diamond) and brain (indicated in white square) at different time point 
following single i.p. injection of 20 mg/kg of GSK247246. For blood pharmacokinetic 
analysis, the GSK247246 concentrations of 24-hour blood samples are below the 
detection limit of quantification assay. B. GSK247246 concentrations in blood and brain 
2h post last dose of 5-day dosing regimen (bid via i.p.) at low (7mg/kg) or high dose (20 
mg/kg). 
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Figure 3. H3R protein expression in the developing mouse brain. H3R was observed 
generally at the cell membrane as expected on cells of the grey and white matter via IHC 
in the P5 mouse brain including in the sensorimotor cortex A (low magnification) & B (high 
magnification) and in the periventricular white matter C (high magnification). Scale bars 
= 100um. 
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Figure 4. Effects of GSK247246 on APC and NG2 cell number in our model of PWMI. 
The administration of GSK247246 between P6 and P10 did not affect APC number but 
decreased the density of NG2 positive cells in P10 mice only in the corpus callosum with 
the 7 mg/kg/injection dose. A. Quantification of APC positive cells was assessed in mice 
at P10 from ≥10 litters of control (PBS treated) mice (Ctrl; n=30) or those subjected to 
neuroinflammation (NI; n=30), or neuroinflammation plus 7 mg/kg/injection GSK247246 
(+GSK-7; n=30) and 20 mg/kg/injection GSK247246 (+GSK-20; n=30) in the corpus 
callosum, the sensorimotor cortex, the cingulate white matter, the external capsule. B. 
Quantification of NG2 positive cells in was assessed in mice from 5-8 litters from P10 
control (PBS treated) mice (Ctrl; n=10, black bars), mice subjected to neuroinflammation 
(NI; n=8), or neuroinflammation plus 7 mg/kg/injection GSK247246 (+GSK-7; n=5) and 
20 mg/kg/injection GSK247246 (+GSK-20; n=5) in the corpus callosum. Results are 
expressed as mean+/- standard deviation. Asterisks indicate statistically significant 
difference from NI data, *p<0.05, ***p<0.001 by Mann-Whitney test. 
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Figure 5. Effects of GSK247246 on MBP expression in our model of PWMI. The 
administration of GSK247246 between P6 and P10 prevented the decrease of MBP 
expression due to neuroinflammation in P30 mice, only in sensorimotor cortical white 
matter with the 7 mg/kg/injection dose. A. Density of MBP positive cells was assessed in 
mice from ≥10 litters using DAB immunostaining in P30 control PBS treated mice (Ctrl; 
n=30), mice subjected to neuroinflammation (NI; n=30), or neuroinflammation plus 7 
mg/kg/injection GSK247246 (+GSK-7; n=30) and 20 mg/kg/injection GSK247246 (+GSK-
20; n=30) within the corpus callosum, the anterior commissure, the sensorimotor cortex, 
the cingulate white matter, the external capsule and the basal ganglia. Results are 
expressed as mean+/- standard deviation. Asterisks indicate statistically significant 
difference from NI data, **p<0.01 and ***p<0.001 by Mann-Whitney test. B. 
Representative photomicrographs of MBP immunostaining in the sensorimotor cortex at 
P30 (scale bar = 100 µm). 
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Figure 6. Effects of GSK247246 on PLP expression in our model of PWMI. The 
administration of GSK247246 between P6 and P10 in our model of PWMI prevented the 
decrease of PLP expression in P30 mice in the anterior commissure, cingulate white 
matter and external capsule with both doses. Density of PLP positive cells was assessed 
in mice from ≥10 litters using DAB immunostaining brain sections in P30 control (PBS 
treated) mice (Ctrl; n=30), mice subjected to neuroinflammation (NI; n=30), or 
neuroinflammation plus 7 mg/kg/injection GSK247246 (+GSK-7; n=30) and 20 
mg/kg/injection GSK247246 (+GSK-20; n=30) within the corpus callosum, the anterior 
commissure, the cingulate white matter and the external capsule. Results are expressed 
as mean+/- standard deviation. Asterisks indicate statistically significant difference from 
NI data, ***p<0.001 by Mann-Whitney test.  
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Figure 7. Effects of GSK247246 on MAG expression in our model of PWMI. The 
administration of 7 mg/kg/injection GSK247246 between P6 and P10 in our model of 
PWMI prevented the decrease of MAG in the corpus callosum and cingulate white matter. 
A. Density of MAG positive cells was assessed in mice from ≥10 litters using DAB 
immunostaining brain sections in P30 control (PBS treated) mice (Ctrl; n=30), mice 
subjected to neuroinflammation (NI; n=30), or neuroinflammation plus 7 mg/kg/injection 
GSK247246 (+GSK-7; n=30) and 20 mg/kg/injection GSK247246 (+GSK-20; n=30) within 
the corpus callosum and the cingulate white matter. Results are expressed as mean+/- 
standard deviation. Asterisks indicate statistically significant difference from NI data, 
***p<0.001 by Mann-Whitney test. B. Photomicrographs of representative MAG 
immunostaining in the corpus callosum at P30 (scale bar = 100 µm). 
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Figure 8. Effects of GSK247246 on myelin and myelin-related gene expression in our 
model of PWMI. Low and high doses of GSK247246 between P6 and P10 did not have 
significant effects on gene expression when compared to the neuroinflammation group, 
except for Egr1. Gene expression analysis of Mag, Mbp, Mog, Gjc2, Id2, Cnpase, Pdgfra, 
Hey2, Dusp1, Egr1, Fos, Sox18 by qRT-PCR on frontal lobes tissue from mice from 5 
litters of control mice (Ctrl; n=5), mice subjected to neuroinflammation (NI; n=5), or 
subjected to neuroinflammation plus 7 mg/kg/injection GSK247246 (+GSK-7; n=5) or 20 
mg/kg/injection GSK247246 (+GSK-20; n=5). Results are expressed as mean+/- 
standard deviation. Asterisks indicate statistically significant difference from NI data, 
*p<0.05, **p<0.01 and ***p<0.001 by Mann-Whitney test.  
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Figure 9. Effects of GSK247246 on cleaved-caspase-3 cell number in our model of 
PWMI. Only high dose GSK247246 significantly increased cell death in P10 mice. 
Quantification of cleaved caspase 3 positive cells from mice from ≥10 litters within the 
corpus callosum, the sensorimotor cortex, the cingulate white matter and the external 
capsule of P10 control mice (Ctrl; n=29), mice subjected to neuroinflammation (NI; n=24), 
or subjected to neuroinflammation plus 7 mg/kg/injection GSK247246 (+GSK-7; n=15) or 
20 mg/kg/injection GSK247246 (+GSK-20; n=15). Results are expressed as mean+/- 
standard deviation. Asterisks indicate statistically significant difference from NI data, 
*p<0.05 and ***p<0.001 by Mann-Whitney test. 
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Figure 10. A. GSK247246 reduces delayed onset NI induced GFAP cell number 
increases. Quantification of GFAP positive cells in the corpus callosum, the sensorimotor 
cortex, the anterior commissure or cingulate white matter and the external capsule. A. 
Tissues were collected from 5 litters of mice at P10, from control mice (Ctrl; n=10), those 
subjected to neuroinflammation (NI; n=8), or subjected to neuroinflammation plus 7 
mg/kg/injection GSK247246 (+GSK-7; n=5) and 20 mg/kg/injection GSK247246 (+GSK-
20; n=5), or B. tissues were collected from ≥10 litters of mice at P30 from control mice 
(Ctrl; n=15), mice subjected to neuroinflammation (NI; n=15), neuroinflammation plus 7 
mg/kg/injection GSK247246 (+GSK-7; n=15) or plus 20 mg/kg/injection GSK247246 
(+GSK-20; n=15). Results are expressed as mean+/- standard deviation. Asterisks 
indicate statistically significant difference from NI data, ***p<0,001 by Mann-Whitney test. 
(C) Representative photomicrographs of GFAP immunostaining at the cingulate white 
matter level at P30 (scale bar = 100 µm). 
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Figure 11. Increased IBA1 positive cell number in the animals subjected to 
neuroinflammation was reduced by GSK247246 in selected regions at P10 and 
P30. Quantification of IBA1 positive cells in the corpus callosum, the sensorimotor cortex, 
the cingulate white matter and the external capsule. A. Tissues were collected from 5 
litters of mice at P10, from control mice (Ctrl; n=10), those subjected to neuroinflammation 
(NI; n=8), or subjected to neuroinflammation plus 7 mg/kg/injection GSK247246 (+GSK-
7; n=5) or plus 20 mg/kg/injection GSK247246 (+GSK-20; n=5). Also B. from tissues from 
≥10 litter at P30 mice in control mice (n=15), those subjected to neuroinflammation 
(n=15), neuroinflammation plus 7 mg/kg/injection GSK247246 (+GSK-7; n=15) or plus 20 
mg/kg/injection GSK247246 (+GSK-20; n=15). Results are expressed as mean+/- 
standard deviation. Asterisks indicate statistically significant difference from NI data, 
*p<0.05 and **p<0.01 by Mann-Whitney test. C. Representative photomicrographs of 
IBA1 immunostaining at the sensory motor cortex level at P30 (scale bar = 100 µm). 
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Supplementary table 1. Primer sequences and NCBI reference for primers for qRT-
PCR.  
 
 
 
 
 
 
 
 
  
Gene Sequences (5’ and 3’ respectively) NCBI reference Amplicon size 
Mag 
GTCTCTACCCGGGATTGTCA 
NM_010758 131 
CCCAGGTCTGAGTGGGAATA 
Mbp CCGGACCCAAGATGAAAAC NM-001025259 77 CTTGGGATGGAGGTGGTGT 
Mog AAGAGGCAGCAATGGAGTTG NM-010814 101 GACCTGCAGGAGGATCGTAG 
Gjc2 CCTTCCTTCCAAGGCTCTCT NM-080454.4 146 TGGGAGTTCTCTGGCTCTGT 
Id2 CTGGACTCGCATCCCACTAT NM_010496 144 CGACATAAGCTCAGAAGGGAAT 
Cnpase AGACAGCGTGGCGACTAGACT NM_009923 85 GGGCTTCAGCTTCTTCAGGT 
Pdgfra GACGTTCAAGACCAGCGAGTT NM_011058 82 CAGTCTGGCGTGCGTCC 
Hey2 TGAAGATGCTCCAGGCTACA NM_013904.1 87 CACTCTCGGAATCCAATGCT 
Dusp1 AGGACAACCACAAGGCAGAC NM_013642.3 142 GAGGTAAGCAAGGCAGATGG 
Egr1 GAGCGAACAACCCTATGAGC NM_007913.5 90 GGGATAACTCGTCTCCACCA 
Fos 
ATGGGCTCTCCTGTCAACAC NM_010234.2 77 TGTCACCGTGGGGATAAAGT 
Sox18 CGCAGTACTGAGCAAGATGC NM_009236.2 134 CGAGGCCGGTACTTGTAGTT 
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Primary 
Name Description 
P5 data O4+ cells P5 data CD11b+ cells 
Fold 
Change P Value 
Fold 
Change P Value 
 
Hrh1 
Mus musculus histamine receptor 
H1 (Hrh1), transcript variant 1, 
mRNA [NM_001252643] 
-1.22029 
 
0.02495 
 
1.182 1.53E-01 
Hrh1 
Mus musculus histamine receptor 
H1 (Hrh1), transcript variant 1, 
mRNA [NM_001252643] 
-1.03229 0.78373 -1.019 7.58E-01 
Hrh1 
Mus musculus histamine receptor 
H1 (Hrh1), transcript variant 1, 
mRNA [NM_001252643] 
1.02724 0.56063 -2.231 5.14E-05 
Hrh2 
Mus musculus histamine receptor 
H1 (Hrh1), transcript variant 1, 
mRNA [NM_001252643] 
 
1.07234 
 
0.81063 1.446 5.26E-01 
Hrh3 Mus musculus histamine receptor H3 (Hrh3), mRNA [NM_133849] 1.27853 0.01658 1.797 1.48E-01 
Hrh4 Mus musculus histamine receptor H4 (Hrh4), mRNA [NM_153087] -1.01397 0.88406 1.329 5.43E-02 
 
Supplementary table 2. Microarray data confirmed the expression of the H3R mRNA in 
O4-positive oligodendrocytes and CD11B-positive microglia at both at P5. Data also 
available for P10 also showing no overt change (Krishnan et al., 2017). 
 
 
